title: Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia.
abstract: Despite remission rates of approximately 85% for children diagnosed with acute myeloid leukemia (AML), greater than 40% will die from relapsed disease. Patients with poor-risk molecular/cytogenetics and/or inadequate response to up-front therapy are typically considered high-risk (HR) and historically have poor outcomes with chemotherapy alone. We investigated whether allogeneic hematopoietic cell transplantation (allo-HCT) with best available donor in first remission (CR1) would abrogate the poor outcomes associated with HR AML in children and young adults treated with chemotherapy. We reviewed the outcomes of 50 consecutive children and young adults (ages 0 to 30 years) with AML who received a myeloablative allo-HCT between 2001 and 2010. Thirty-six patients (72%) were HR, defined as having FLT3-ITD mutations, 11q23 MLL rearrangements, chromosome 5 or 7 abnormalities, induction failure, and/or having persistent disease. The majority of patients received cyclophosphamide and total body irradiation conditioning, and graft-versus-host-disease (GVHD) prophylaxis was cyclosporine based. Transplantation outcomes for HR patients were compared to standard-risk patients, with no significant differences observed in overall survival (72% versus 78%, P = .72), leukemia-free survival (69% versus 79%, P = .62), relapse (11% versus 7%, P = .71), or treatment-related mortality (17% versus 14%, P = .89). Children and young adults with HR-AML have comparable outcomes to standard-risk patients following allo-HCT in CR1.
authors.affiliation: Division of Pediatric Hematology-Oncology, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN, USA. burke283@umn.edu
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Burke
authors.forename: John E
authors.initials: JE
authors.lastname: Wagner
authors.forename: Qing
authors.initials: Q
authors.lastname: Cao
authors.forename: Celalettin
authors.initials: C
authors.lastname: Ustun
authors.forename: Michael R
authors.initials: MR
authors.lastname: Verneris
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D002895:Chromosomes, Human, Pair 5; D002897:Chromosomes, Human, Pair 7; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D008297:Male; D009154:Mutation; D019653:Myeloablative Agonists / Q000627:therapeutic use; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D012306:Risk; D016019:Survival Analysis; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D019653:Myeloablative Agonists; D015514:Oncogene Proteins, Fusion